PPID polyclonal antibody
- Known as:
- PPID pab (anti-)
- Catalog number:
- PAB19543
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- PPID polyclonal antibody
Related genes to: PPID polyclonal antibody
- Gene:
- PPID NIH gene
- Name:
- peptidylprolyl isomerase D
- Previous symbol:
- -
- Synonyms:
- CYP-40
- Chromosome:
- 4q32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-23
- Date modifiied:
- 2016-10-05
Related products to: PPID polyclonal antibody
Related articles to: PPID polyclonal antibody
- Ertugliflozin is a sodium-glucose co-transporter-2 inhibitor that has demonstrated promise as a treatment for hyperinsulinaemia in horses. Despite the frequent use of ertugliflozin in equine clinical practice, the pharmacokinetics of this drug in horses has not been established. The aim of the present study was to determine the pharmacokinetics of one supratherapeutic dose (0.25 mg/kg) of ertugliflozin in eight horses. Horses were defined as being healthy by physical examination, haematological, blood biochemical and oral sugar test (OST) results. Plasma concentrations of ertugliflozin were quantified using high-performance liquid chromatography-tandem mass spectrometry 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 14, 18, 24, 30, 36, 48, 60, 72, 96, and 120 h after drug administration enterally. Non-compartmental analysis led to determination of key pharmacokinetic variables, including mean ± SD time to maximum concentration (T of 0.91 ± 0.13 h, maximum measured concentration (C of 267.52 ± 25.37 ng/mL, terminal elimination half-life (T) of 17.65 ± 3.15 h and apparent oral clearance (CL/F) of 106.95 ± 27.53 mL/h/kg. No clinical signs of adverse effects or blood biochemical abnormalities occurred after drug administration. The results of this study suggest that a single supratherapeutic dose of ertugliflozin in healthy horses is safe. The pharmacokinetics of enterally administered ertugliflozin in horses are similar to pharmacokinetics of the drug in humans and the long T makes ertugliflozin suitable for once daily dosing in horses. It is proposed that a starting dose for ertugliflozin in horses be in the range 0.05-0.1 mg/kg. Further pharmacokinetic studies are required to optimise the dose regimen for treating horses with hyperinsulinaemia. - Source: PubMed
Publication date: 2026/05/01
Kirkwood Naomi CHughes Kristopher JLovett Amy LDoran Gregory SRendle David IEdwards Scott H - Bedside transfusion errors, especially positive patient identification (PPID), are a risk to patient safety. Bedside electronic transfusion checks (BETC), using barcode-enabled personal digital assistants (PDAs), are recommended to improve safety and efficiency. This study assessed staff satisfaction with BETC versus manual transfusion checks in three large London hospitals. The surveys aimed to compare clinical staff satisfaction with BETC versus the manual system. - Source: PubMed
Publication date: 2026/05/06
Oyekan FlorenceAhmed MontasirBooth CatherineBowles LouiseDjurdjevic OllieFeng YanHancock KirstyMakki SuzanneMcAleese HelinorMcCullagh JosephineMon KhinMurphy Michael FStanworth Simon JProudlove NathanGreen Laura - Diagnosis of PPID in horses relies on measurement of plasma adrenocorticotrophic hormone (ACTH) concentrations. Because measured ACTH values vary between analytical platforms, and published diagnostic thresholds apply almost exclusively to the Immulite 1000 chemiluminescent assay (CLA), there is a need for validated, assay-specific thresholds for contemporary analysers. This study aimed to transfer and validate established Immulite 1000 diagnostic thresholds for plasma ACTH to three contemporary systems (Immulite 2000XPi, Tosoh AIA-900, and Tosoh AIA-360) using the Clinical Laboratory Standards Institute (CLSI) guidelines. Surplus clinical EDTA plasma samples were analysed across pairs of analysers to enable method comparison and reference interval transference. The Immulite 2000XPi showed close agreement with the Immulite 1000 (r=0.962, P<0.0001; bias -3.9 pg/mL (95% CI: -12.2-4.4)), enabling reliable linear transference of thresholds. Comparison of Immulite 2000XPi with the AIA-900 revealed moderate correlation and non-linear, concentration-dependent bias (r=0.770, P<0.0001; bias 30.8 pg/mL (95% CI: -110-171)), necessitating threshold-specific regression. The AIA-360 and AIA-900 showed excellent agreement (r=0.993, P<0.0001; bias 4.023 pg/mL (95% CI: -1.4-9.4)). Platform-specific low (90% sensitivity) and high (90% specificity) diagnostic thresholds were generated for four seasonal periods for all analysers. The proposed analyser-specific thresholds provide clinicians and laboratories with more validated guidance for interpreting plasma ACTH results across contemporary analysers, supporting more accurate diagnosis and management of PPID in horses. - Source: PubMed
Publication date: 2026/04/23
Durham Andy ELopes Ana - Uropathogenic (UPEC) is the primary etiological agent of urinary tract infections (UTIs) worldwide. The emergence of strains combining high virulence with multidrug resistance (MDR) poses a significant challenge to public health. This study aimed to characterize the phylogenetic distribution, virulence profiles, and antimicrobial susceptibility of UPEC isolates recovered from patients in the metropolitan area of Buenos Aires (AMBA), Argentina. Phylogenetic groups, the ST131 lineage, and virulence-associated genes were identified using PCR-based assays. Antimicrobial susceptibility testing (AST) was performed using automated methods and extended-spectrum beta-lactamase (ESBL) production was confirmed using the double-disk synergy test. Colistin (COL) resistance was evaluated by Colistin Drop Test and PCR screening for the (mobile colistin resistance gene 1). Biofilm formation was detected by the Tissue Culture Plate (TCP) method, whereas phenotypic virulence factors (VF) were assessed with Congo Red agar, hemagglutination, and hemolysis assays. Phylogenetic groups B2 (43.8%) and D (26.7%), typically associated with extraintestinal infections, were the most frequent. The high-risk clone B2-ST131 was detected in 6.7% of isolates. Biofilm production was observed in 92.4% of the isolates, with curli fimbriae (87.6%) being the most frequently expressed VF. The highest resistance rates were observed for ampicillin (62.1%), ampicillin-sulbactam (39.8%), and trimethoprim-sulfamethoxazole (25.2%). Interestingly, 3.8% of isolates exhibited colistin resistance, despite the absence of the gene. This study highlights the detection of MDR-UPEC isolates that showed strong resistance to fluoroquinolones and were ESBL producers with high virulence in Argentina, justifying future research encompassing genomic and epidemiological monitoring of local UPEC, which is essential for managing infections and developing new therapeutic and preventive measures. - Source: PubMed
Publication date: 2026/03/29
Molina Nora BGonzález Pasayo Ramón ALópez Marisa ASparo Mónica D - Host factors that promote or restrict human immunodeficiency virus (HIV) infection in human CD4+ T cells have not been comprehensively identified. We employed orthogonal genome-wide CRISPR activation (CRISPRa) and CRISPR knockout screens in primary CD4+ T cells to discover pro- and anti-HIV host factors systematically. Secondary pooled screens and individual perturbations validated high-confidence hits and revealed diverse mechanisms of action. CRISPRa uncovered multiple potent antiviral factors, including PI16, PPID, SHISA3, and ITM2A. PI16 interacts with host factors involved in HIV fusion and inhibits viral entry, whereas PPID (Cyp40), a paralog of the proviral cyclophilin CypA, binds capsid and reduces nuclear import of the HIV core. Structural modeling, evolutionary analyses, and targeted mutagenesis revealed domains and residues required for PPID-mediated HIV restriction, including non-human primate ortholog substitutions that enhance antiviral activity. Together, these data define the functional HIV-host interaction landscape in primary human T cells and uncover new mechanisms modulating infection. - Source: PubMed
Publication date: 2026/04/20
Rathore UjjwalDugan EliThornton HunterKumar Vigneshwari EaswarDajani RamaBurdick Ryan CYoung Janet MSteinhart ZacharyLao ReannaDelviks-Frankenberry Krista AChoi WooyoungHenriques William SEcheverria IgnaciaDann EmmaDureja IshaanPathak NandiniArce Maya MMcKetney JustinUmhoefer Jennifer MParulekar SimrunSchmidt RalfPolacco Benjamin JNeidleman JasonMontano MauricioNguyen Vinh QSali AndrejLevy Jay ATenthorey Jeannette LCheng YifanRoan Nadia RSwaney Danielle LKaake Robyn MDodgson Stacie EHiatt JosephPathak Vinay KMalik Harmit SKrogan Nevan JMarson Alexander